Uganda sought to dispel fears among HIV patients that a US aid freeze will interrupt treatment and promised that such programs will continue.

The Trump administration has moved to stop the supply of lifesaving drugs for HIV, malaria, and tuberculosis in countries supported by USAID around the globe.

A move by the Trump administration to freeze funding for PEPFAR, the widely heralded international HIV/AIDS program, is putting countless lives at immediate risk, experts say.

Secretary of State Marco Rubio announced the waiver on Tuesday; however, exactly what it covers remains unclear. While the waiver does allow for the resumption of distributing HIV medications, the freeze on other services, including the distribution of preventive drugs, is still thought to be in place.

A stop in all of PEPFAR’s work shuttered clinics this week. Then, a new exemption for “life-saving” treatment left organizations uncertain.

The President’s Emergency Plan for AIDS Relief (PEPFAR), a federal program that provides HIV medications, is one of the programs on pause during a 90-day review ordered by the Secretary of State.

The World Health Organization (WHO) expresses deep concern on the implications of the immediate funding pause for HIV programmes in low- and middle-income countries.

Almost 1 in 10 patients receiving HIV care may have binge eating disorder (BED), a significantly higher rate than the 0.3% reported in the general population, according to a cross-sectional study. Individuals with possible BED were six times more likely than others to have clinical obesity and twice as likely to be overweight.

In patients with HIV, alcohol reduction after a 6-month intervention and adherence to isoniazid had no effect on the high levels of viral suppression reported at baseline.

Almost 136,000 babies are expected to be born with HIV in the next three months, mostly in Africa, because of the Trump administration’s “stop work order” on foreign assistance, according to a top research foundation.

Major barriers in screening for fatty liver disease in patients with HIV included uncertainties about testing, diagnostic data insufficiency, low priority, time constraints, and referral limitations.